Christina Takke co-founded V-Bio Ventures in 2015 and is currently a Managing Partner of the firm. Before launching V-Bio Ventures, Christina was a partner at Forbion Capital Partners (previously ABN AMRO Capital) were she led and managed a series of successful investments in biopharmaceutical and pharmaceutical companies.As an undergraduate Christina studied Molecular Biology / Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the Institut National de la Recherche Agronomique (INRA) Montpellier.  She holds a PhD in Developmental Biology, which she obtained at the Institute of Development Biology of the University of Cologne. Christina currently serves on the board of V-Bio’s portfolio companies Confo Therapeutics NV, Octimet NV, Oxular Ltd,  Precirix NV and Syndesi SA. In recent years she served among others on the board of argenx NV.